Do analysts prefer XTLB or AIMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TPST or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TPST or XTLB more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% XTL Biopharmaceuticals N/A N/A N/A

Do analysts recommend LPCN or XTLB?

Lipocine currently has a consensus target price of $15.00, suggesting a potential upside of 563.72%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate XTLB or NCEL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, XTLB or NCEL?

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XTL Biopharmaceuticals $450K 10.41 -$1.03M -$0.64 N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is XTLB or NCEL more profitable?

Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A NLS Pharmaceutics N/A N/A N/A

Do analysts rate XTLB or CTXR?

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 825.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is XTLB or CTXR more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Citius Pharmaceuticals N/A -61.09% -35.36%

XTL Biopharmaceuticals (XTLB) Competitors

$2.13 -0.21 (-8.97%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 -0.09 (-4.18%)

As of 07:50 PM Eastern

Compare

XTLB vs. AIMD, TPST, LPCN, NCEL, and CTXR

Should you buy XTL Biopharmaceuticals stock or one of its competitors? MarketBeat compares XTL Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XTL Biopharmaceuticals include Ainos (AIMD), Tempest Therapeutics (TPST), Lipocine (LPCN), NLS Pharmaceutics (NCEL), and Citius Pharmaceuticals (CTXR). These companies are all part of the "med - drugs" industry.

How does XTL Biopharmaceuticals compare to Ainos?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

XTL Biopharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. XTL Biopharmaceuticals' return on equity of 0.00% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Ainos	-11,912.10%	-160.55%	-62.29%

In the previous week, Ainos had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Ainos and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat Ainos' score of 0.48 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Positive
Ainos	Neutral

XTL Biopharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Ainos has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XTL Biopharmaceuticals has higher revenue and earnings than Ainos. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A
Ainos	$120K	135.61	-$14.77M	-$2.89	N/A

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

XTL Biopharmaceuticals beats Ainos on 9 of the 13 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Tempest Therapeutics has a beta of -1.85, indicating that its stock price is 285% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 6.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XTL Biopharmaceuticals' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
XTL Biopharmaceuticals	N/A	N/A	N/A

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for XTL Biopharmaceuticals and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.87 beat XTL Biopharmaceuticals' score of 1.44 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Very Positive
XTL Biopharmaceuticals	Positive

XTL Biopharmaceuticals has higher revenue and earnings than Tempest Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A

Summary

XTL Biopharmaceuticals beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Lipocine has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

XTL Biopharmaceuticals has lower revenue, but higher earnings than Lipocine. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.41	-$9.63M	-$1.88	N/A
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A

9.1% of Lipocine shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lipocine and Lipocine both had 2 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat Lipocine's score of 0.94 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Lipocine	Positive
XTL Biopharmaceuticals	Positive

XTL Biopharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XTL Biopharmaceuticals' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
XTL Biopharmaceuticals	N/A	N/A	N/A

Lipocine currently has a consensus target price of $15.00, suggesting a potential upside of 563.72%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

XTL Biopharmaceuticals beats Lipocine on 9 of the 15 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, XTL Biopharmaceuticals and XTL Biopharmaceuticals both had 2 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat NLS Pharmaceutics' score of 0.94 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Positive
NLS Pharmaceutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
NLS Pharmaceutics	N/A	N/A	N/A

XTL Biopharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

Summary

XTL Biopharmaceuticals beats NLS Pharmaceutics on 6 of the 6 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Citius Pharmaceuticals?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

XTL Biopharmaceuticals has higher revenue and earnings than Citius Pharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

In the previous week, XTL Biopharmaceuticals and XTL Biopharmaceuticals both had 2 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat Citius Pharmaceuticals' score of 0.76 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Positive
Citius Pharmaceuticals	Positive

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 825.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

XTL Biopharmaceuticals' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

XTL Biopharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

XTL Biopharmaceuticals beats Citius Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XTLB vs. The Competition

Export

Metric	XTL Biopharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.16M	$2.99B	$6.75B	$12.02B
Dividend Yield	N/A	1.76%	2.66%	5.61%
P/E Ratio	-3.33	12.59	20.34	22.43
Price / Sales	10.41	302.43	510.75	109.73
Price / Cash	N/A	56.52	44.01	55.64
Price / Book	0.86	3.99	10.66	6.79
Net Income	-$1.03M	$75.85M	$3.56B	$337.66M
7 Day Performance	3.40%	1.07%	0.05%	2.08%
1 Month Performance	-18.39%	-3.27%	0.37%	3.16%
1 Year Performance	N/A	20.00%	22.73%	27.78%

XTL Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XTLB XTL Biopharmaceuticals	1.2864 of 5 stars	$2.13 -9.0%	N/A	N/A	$5.16M	$450K	N/A	N/A	Positive News Short Interest Decrease Gap Down
AIMD Ainos	0.6355 of 5 stars	$2.20 -6.8%	N/A	-30.9%	$20.12M	$120K	N/A	40	Short Interest Increase
TPST Tempest Therapeutics	2.5202 of 5 stars	$1.27 -3.1%	N/A	-83.3%	$19.40M	N/A	N/A	20	Positive News
LPCN Lipocine	4.4171 of 5 stars	$2.19 -2.7%	$15.00 +584.9%	-33.9%	$18.55M	$1.98M	N/A	10	News Coverage Gap Down
NCEL NLS Pharmaceutics	1.245 of 5 stars	$3.16 -4.8%	N/A	-86.5%	$17.75M	N/A	N/A	6	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XTLB) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. AIMD, TPST, LPCN, NCEL, and CTXR

How does XTL Biopharmaceuticals compare to Ainos?

Summary

How does XTL Biopharmaceuticals compare to Tempest Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to Lipocine?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Summary

How does XTL Biopharmaceuticals compare to Citius Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. AIMD, TPST, LPCN, NCEL, and CTXR

How does XTL Biopharmaceuticals compare to Ainos?

Is XTLB or AIMD more profitable?

Does the media favor XTLB or AIMD?

Which has more risk and volatility, XTLB or AIMD?

Do analysts prefer XTLB or AIMD?

Which has higher valuation and earnings, XTLB or AIMD?

Do institutionals and insiders believe in XTLB or AIMD?

Summary

How does XTL Biopharmaceuticals compare to Tempest Therapeutics?

Which has more risk & volatility, TPST or XTLB?

Do institutionals & insiders hold more shares of TPST or XTLB?

Do analysts prefer TPST or XTLB?

Is TPST or XTLB more profitable?

Does the media refer more to TPST or XTLB?

Which has preferable valuation and earnings, TPST or XTLB?

Summary

How does XTL Biopharmaceuticals compare to Lipocine?

Which has more volatility and risk, LPCN or XTLB?

Which has better earnings and valuation, LPCN or XTLB?

Do insiders & institutionals hold more shares of LPCN or XTLB?

Does the media prefer LPCN or XTLB?

Is LPCN or XTLB more profitable?

Do analysts recommend LPCN or XTLB?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Do insiders and institutionals believe in XTLB or NCEL?

Does the media favor XTLB or NCEL?

Do analysts rate XTLB or NCEL?

Is XTLB or NCEL more profitable?

Which has more risk and volatility, XTLB or NCEL?

Which has preferable earnings and valuation, XTLB or NCEL?

Summary

How does XTL Biopharmaceuticals compare to Citius Pharmaceuticals?

Which has stronger earnings and valuation, XTLB or CTXR?

Does the media favor XTLB or CTXR?

Do analysts rate XTLB or CTXR?

Is XTLB or CTXR more profitable?

Which has more volatility and risk, XTLB or CTXR?

Do insiders and institutionals hold more shares of XTLB or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools